Credit Suisse’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Credit Suisse’s Portfolio IRLA Stock Details IRLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Hold	0	–	–	–	4235
2022 Q2	–	Sell	-55	Closed	-$38.9K	–	4232
2022 Q1	$68K	Buy	55 +5	+10%	+$6.8K	﹤0.01%	3500
2021 Q4	$127K	Sell	50 -2	-4%	-$12.2K	﹤0.01%	4357
2021 Q3	$946K	Buy	52 +4	+8%	+$63.6K	﹤0.01%	3393
2021 Q2	$509K	Sell	48 -9	-16%	-$75.5K	﹤0.01%	3823
2021 Q1	$409K	Sell	57 -87	-60%	-$626K	﹤0.01%	3883
2020 Q4	$799K	Buy	144 +104	+260%	+$921K	﹤0.01%	3495
2020 Q3	$399K	Sell	40 -7	-15%	-$63.7K	﹤0.01%	3506
2020 Q2	$435K	Buy	+47	New	+$431K	﹤0.01%	3399
2019 Q3	–	Sell	-34	Closed	-$289K	–	4229
2019 Q2	$289K	Buy	+34	New	+$203K	﹤0.01%	3697

Other funds holding IRLA

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $3.16B AUM 42.38% 1-Year Est. Return

Credit Suisse's IRLA Position: Q3 2022 in Review

Credit Suisse held its IRulya Therapeutics Inc. Common Stock (IRLA) position steady in Q3 2022 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #4235.

Credit Suisse first reported a position in IRLA in Q2 2019 and has held it in 9 quarters since. The position peaked at $946K in Q3 2021. 58 funds tracked by Wall St. Rank hold IRLA as of Q3 2022.

Credit Suisse held 0 shares of IRulya Therapeutics Inc. Common Stock worth $0 as of Q3 2022.
Credit Suisse left its IRulya Therapeutics Inc. Common Stock share count unchanged in Q3 2022.
IRulya Therapeutics Inc. Common Stock made up ﹤0.01% of Credit Suisse's portfolio in Q3 2022, its #4235 holding.
Credit Suisse first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2019 and has held it in 9 quarters since.
Credit Suisse's IRulya Therapeutics Inc. Common Stock position peaked at $946K in Q3 2021.
58 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q3 2022.

Based on Credit Suisse's 13F filing for Q3 2022, filed 10 Nov 2022.